Prospective prevalence of pathologic gambling and medication association in Parkinson disease
Identifieur interne : 000836 ( PascalFrancis/Corpus ); précédent : 000835; suivant : 000837Prospective prevalence of pathologic gambling and medication association in Parkinson disease
Auteurs : V. Voon ; K. Hassan ; M. Zurowski ; S. Duff-Canning ; M. De Souza ; S. Fox ; A. E. Lang ; J. MiyasakiSource :
- Neurology [ 0028-3878 ] ; 2006.
Descripteurs français
- Pascal (Inist)
English descriptors
Abstract
The authors prospectively screened 297 patients with Parkinson disease (PD), who attended a tertiary clinic, using a modified South Oaks Gambling Scale. Lifetime prevalence of pathologic gambling (PG) was 3.4% and on any dopamine agonist was 7.2%. PG was associated with earlier PD onset and with dopamine agonists but not with agonist subtype or doses. We found no association with a potent D3 receptor agonist.
Notice en format standard (ISO 2709)
Pour connaître la documentation sur le format Inist Standard.
pA |
|
---|
Format Inist (serveur)
NO : | PASCAL 06-0327369 INIST |
---|---|
ET : | Prospective prevalence of pathologic gambling and medication association in Parkinson disease |
AU : | VOON (V.); HASSAN (K.); ZUROWSKI (M.); DUFF-CANNING (S.); DE SOUZA (M.); FOX (S.); LANG (A. E.); MIYASAKI (J.) |
AF : | Human Motor Control Section, National Institute of Neurological Disorders and Stroke, National Institutes of Health/Bethesda, MD/Etats-Unis (1 aut.); Department of Psychiatry, Toronto Western Hospital/Toronto/Canada (1 aut., 3 aut., 5 aut.); Division of Neurology, Toronto Western Hospital/Toronto/Canada (2 aut., 4 aut., 6 aut., 7 aut., 8 aut.) |
DT : | Publication en série; Niveau analytique |
SO : | Neurology; ISSN 0028-3878; Coden NEURAI; Etats-Unis; Da. 2006; Vol. 66; No. 11; Pp. 1750-1752; Bibl. 10 ref. |
LA : | Anglais |
EA : | The authors prospectively screened 297 patients with Parkinson disease (PD), who attended a tertiary clinic, using a modified South Oaks Gambling Scale. Lifetime prevalence of pathologic gambling (PG) was 3.4% and on any dopamine agonist was 7.2%. PG was associated with earlier PD onset and with dopamine agonists but not with agonist subtype or doses. We found no association with a potent D3 receptor agonist. |
CC : | 002B17; 002B17G; 002B17A03 |
FD : | Système nerveux pathologie; Parkinson maladie; Prospective; Prévalence; Chimiothérapie |
FG : | Encéphale pathologie; Extrapyramidal syndrome; Maladie dégénérative; Système nerveux central pathologie |
ED : | Nervous system diseases; Parkinson disease; Prospective; Prevalence; Chemotherapy |
EG : | Cerebral disorder; Extrapyramidal syndrome; Degenerative disease; Central nervous system disease |
SD : | Sistema nervioso patología; Parkinson enfermedad; Prospectiva; Prevalencia; Quimioterapia |
LO : | INIST-6345.354000115605140300 |
ID : | 06-0327369 |
Links to Exploration step
Pascal:06-0327369Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Prospective prevalence of pathologic gambling and medication association in Parkinson disease</title>
<author><name sortKey="Voon, V" sort="Voon, V" uniqKey="Voon V" first="V." last="Voon">V. Voon</name>
<affiliation><inist:fA14 i1="01"><s1>Human Motor Control Section, National Institute of Neurological Disorders and Stroke, National Institutes of Health</s1>
<s2>Bethesda, MD</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="02"><s1>Department of Psychiatry, Toronto Western Hospital</s1>
<s2>Toronto</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Hassan, K" sort="Hassan, K" uniqKey="Hassan K" first="K." last="Hassan">K. Hassan</name>
<affiliation><inist:fA14 i1="03"><s1>Division of Neurology, Toronto Western Hospital</s1>
<s2>Toronto</s2>
<s3>CAN</s3>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Zurowski, M" sort="Zurowski, M" uniqKey="Zurowski M" first="M." last="Zurowski">M. Zurowski</name>
<affiliation><inist:fA14 i1="02"><s1>Department of Psychiatry, Toronto Western Hospital</s1>
<s2>Toronto</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Duff Canning, S" sort="Duff Canning, S" uniqKey="Duff Canning S" first="S." last="Duff-Canning">S. Duff-Canning</name>
<affiliation><inist:fA14 i1="03"><s1>Division of Neurology, Toronto Western Hospital</s1>
<s2>Toronto</s2>
<s3>CAN</s3>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="De Souza, M" sort="De Souza, M" uniqKey="De Souza M" first="M." last="De Souza">M. De Souza</name>
<affiliation><inist:fA14 i1="02"><s1>Department of Psychiatry, Toronto Western Hospital</s1>
<s2>Toronto</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Fox, S" sort="Fox, S" uniqKey="Fox S" first="S." last="Fox">S. Fox</name>
<affiliation><inist:fA14 i1="03"><s1>Division of Neurology, Toronto Western Hospital</s1>
<s2>Toronto</s2>
<s3>CAN</s3>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Lang, A E" sort="Lang, A E" uniqKey="Lang A" first="A. E." last="Lang">A. E. Lang</name>
<affiliation><inist:fA14 i1="03"><s1>Division of Neurology, Toronto Western Hospital</s1>
<s2>Toronto</s2>
<s3>CAN</s3>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Miyasaki, J" sort="Miyasaki, J" uniqKey="Miyasaki J" first="J." last="Miyasaki">J. Miyasaki</name>
<affiliation><inist:fA14 i1="03"><s1>Division of Neurology, Toronto Western Hospital</s1>
<s2>Toronto</s2>
<s3>CAN</s3>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">06-0327369</idno>
<date when="2006">2006</date>
<idno type="stanalyst">PASCAL 06-0327369 INIST</idno>
<idno type="RBID">Pascal:06-0327369</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000836</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Prospective prevalence of pathologic gambling and medication association in Parkinson disease</title>
<author><name sortKey="Voon, V" sort="Voon, V" uniqKey="Voon V" first="V." last="Voon">V. Voon</name>
<affiliation><inist:fA14 i1="01"><s1>Human Motor Control Section, National Institute of Neurological Disorders and Stroke, National Institutes of Health</s1>
<s2>Bethesda, MD</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="02"><s1>Department of Psychiatry, Toronto Western Hospital</s1>
<s2>Toronto</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Hassan, K" sort="Hassan, K" uniqKey="Hassan K" first="K." last="Hassan">K. Hassan</name>
<affiliation><inist:fA14 i1="03"><s1>Division of Neurology, Toronto Western Hospital</s1>
<s2>Toronto</s2>
<s3>CAN</s3>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Zurowski, M" sort="Zurowski, M" uniqKey="Zurowski M" first="M." last="Zurowski">M. Zurowski</name>
<affiliation><inist:fA14 i1="02"><s1>Department of Psychiatry, Toronto Western Hospital</s1>
<s2>Toronto</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Duff Canning, S" sort="Duff Canning, S" uniqKey="Duff Canning S" first="S." last="Duff-Canning">S. Duff-Canning</name>
<affiliation><inist:fA14 i1="03"><s1>Division of Neurology, Toronto Western Hospital</s1>
<s2>Toronto</s2>
<s3>CAN</s3>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="De Souza, M" sort="De Souza, M" uniqKey="De Souza M" first="M." last="De Souza">M. De Souza</name>
<affiliation><inist:fA14 i1="02"><s1>Department of Psychiatry, Toronto Western Hospital</s1>
<s2>Toronto</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Fox, S" sort="Fox, S" uniqKey="Fox S" first="S." last="Fox">S. Fox</name>
<affiliation><inist:fA14 i1="03"><s1>Division of Neurology, Toronto Western Hospital</s1>
<s2>Toronto</s2>
<s3>CAN</s3>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Lang, A E" sort="Lang, A E" uniqKey="Lang A" first="A. E." last="Lang">A. E. Lang</name>
<affiliation><inist:fA14 i1="03"><s1>Division of Neurology, Toronto Western Hospital</s1>
<s2>Toronto</s2>
<s3>CAN</s3>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Miyasaki, J" sort="Miyasaki, J" uniqKey="Miyasaki J" first="J." last="Miyasaki">J. Miyasaki</name>
<affiliation><inist:fA14 i1="03"><s1>Division of Neurology, Toronto Western Hospital</s1>
<s2>Toronto</s2>
<s3>CAN</s3>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Neurology</title>
<title level="j" type="abbreviated">Neurology</title>
<idno type="ISSN">0028-3878</idno>
<imprint><date when="2006">2006</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Neurology</title>
<title level="j" type="abbreviated">Neurology</title>
<idno type="ISSN">0028-3878</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Chemotherapy</term>
<term>Nervous system diseases</term>
<term>Parkinson disease</term>
<term>Prevalence</term>
<term>Prospective</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Système nerveux pathologie</term>
<term>Parkinson maladie</term>
<term>Prospective</term>
<term>Prévalence</term>
<term>Chimiothérapie</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">The authors prospectively screened 297 patients with Parkinson disease (PD), who attended a tertiary clinic, using a modified South Oaks Gambling Scale. Lifetime prevalence of pathologic gambling (PG) was 3.4% and on any dopamine agonist was 7.2%. PG was associated with earlier PD onset and with dopamine agonists but not with agonist subtype or doses. We found no association with a potent D3 receptor agonist.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0028-3878</s0>
</fA01>
<fA02 i1="01"><s0>NEURAI</s0>
</fA02>
<fA03 i2="1"><s0>Neurology</s0>
</fA03>
<fA05><s2>66</s2>
</fA05>
<fA06><s2>11</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Prospective prevalence of pathologic gambling and medication association in Parkinson disease</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>VOON (V.)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>HASSAN (K.)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>ZUROWSKI (M.)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>DUFF-CANNING (S.)</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>DE SOUZA (M.)</s1>
</fA11>
<fA11 i1="06" i2="1"><s1>FOX (S.)</s1>
</fA11>
<fA11 i1="07" i2="1"><s1>LANG (A. E.)</s1>
</fA11>
<fA11 i1="08" i2="1"><s1>MIYASAKI (J.)</s1>
</fA11>
<fA14 i1="01"><s1>Human Motor Control Section, National Institute of Neurological Disorders and Stroke, National Institutes of Health</s1>
<s2>Bethesda, MD</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>Department of Psychiatry, Toronto Western Hospital</s1>
<s2>Toronto</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
</fA14>
<fA14 i1="03"><s1>Division of Neurology, Toronto Western Hospital</s1>
<s2>Toronto</s2>
<s3>CAN</s3>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</fA14>
<fA20><s1>1750-1752</s1>
</fA20>
<fA21><s1>2006</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>6345</s2>
<s5>354000115605140300</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2006 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>10 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>06-0327369</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Neurology</s0>
</fA64>
<fA66 i1="01"><s0>USA</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>The authors prospectively screened 297 patients with Parkinson disease (PD), who attended a tertiary clinic, using a modified South Oaks Gambling Scale. Lifetime prevalence of pathologic gambling (PG) was 3.4% and on any dopamine agonist was 7.2%. PG was associated with earlier PD onset and with dopamine agonists but not with agonist subtype or doses. We found no association with a potent D3 receptor agonist.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B17</s0>
</fC02>
<fC02 i1="02" i2="X"><s0>002B17G</s0>
</fC02>
<fC02 i1="03" i2="X"><s0>002B17A03</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Système nerveux pathologie</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Nervous system diseases</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Sistema nervioso patología</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Parkinson maladie</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Parkinson disease</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Parkinson enfermedad</s0>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Prospective</s0>
<s5>09</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Prospective</s0>
<s5>09</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Prospectiva</s0>
<s5>09</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Prévalence</s0>
<s5>10</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Prevalence</s0>
<s5>10</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Prevalencia</s0>
<s5>10</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Chimiothérapie</s0>
<s5>11</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Chemotherapy</s0>
<s5>11</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Quimioterapia</s0>
<s5>11</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Encéphale pathologie</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Cerebral disorder</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Encéfalo patología</s0>
<s5>37</s5>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Extrapyramidal syndrome</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Extrapyramidal syndrome</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Extrapiramidal síndrome</s0>
<s5>38</s5>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Maladie dégénérative</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Degenerative disease</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Enfermedad degenerativa</s0>
<s5>39</s5>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Système nerveux central pathologie</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Central nervous system disease</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Sistema nervosio central patología</s0>
<s5>40</s5>
</fC07>
<fN21><s1>212</s1>
</fN21>
<fN44 i1="01"><s1>OTO</s1>
</fN44>
<fN82><s1>OTO</s1>
</fN82>
</pA>
</standard>
<server><NO>PASCAL 06-0327369 INIST</NO>
<ET>Prospective prevalence of pathologic gambling and medication association in Parkinson disease</ET>
<AU>VOON (V.); HASSAN (K.); ZUROWSKI (M.); DUFF-CANNING (S.); DE SOUZA (M.); FOX (S.); LANG (A. E.); MIYASAKI (J.)</AU>
<AF>Human Motor Control Section, National Institute of Neurological Disorders and Stroke, National Institutes of Health/Bethesda, MD/Etats-Unis (1 aut.); Department of Psychiatry, Toronto Western Hospital/Toronto/Canada (1 aut., 3 aut., 5 aut.); Division of Neurology, Toronto Western Hospital/Toronto/Canada (2 aut., 4 aut., 6 aut., 7 aut., 8 aut.)</AF>
<DT>Publication en série; Niveau analytique</DT>
<SO>Neurology; ISSN 0028-3878; Coden NEURAI; Etats-Unis; Da. 2006; Vol. 66; No. 11; Pp. 1750-1752; Bibl. 10 ref.</SO>
<LA>Anglais</LA>
<EA>The authors prospectively screened 297 patients with Parkinson disease (PD), who attended a tertiary clinic, using a modified South Oaks Gambling Scale. Lifetime prevalence of pathologic gambling (PG) was 3.4% and on any dopamine agonist was 7.2%. PG was associated with earlier PD onset and with dopamine agonists but not with agonist subtype or doses. We found no association with a potent D3 receptor agonist.</EA>
<CC>002B17; 002B17G; 002B17A03</CC>
<FD>Système nerveux pathologie; Parkinson maladie; Prospective; Prévalence; Chimiothérapie</FD>
<FG>Encéphale pathologie; Extrapyramidal syndrome; Maladie dégénérative; Système nerveux central pathologie</FG>
<ED>Nervous system diseases; Parkinson disease; Prospective; Prevalence; Chemotherapy</ED>
<EG>Cerebral disorder; Extrapyramidal syndrome; Degenerative disease; Central nervous system disease</EG>
<SD>Sistema nervioso patología; Parkinson enfermedad; Prospectiva; Prevalencia; Quimioterapia</SD>
<LO>INIST-6345.354000115605140300</LO>
<ID>06-0327369</ID>
</server>
</inist>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/PascalFrancis/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000836 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 000836 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Canada |area= ParkinsonCanadaV1 |flux= PascalFrancis |étape= Corpus |type= RBID |clé= Pascal:06-0327369 |texte= Prospective prevalence of pathologic gambling and medication association in Parkinson disease }}
![]() | This area was generated with Dilib version V0.6.29. | ![]() |